Revolution Medicines has started distributing its experimental drug daraxonrasib for early access to pancreatic cancer patients, following FDA authorization. The treatment showed remarkable results in extending patient survival.
CHICAGO – Biotech company Revolution Medicines has initiated the shipment of its experimental drug, daraxonrasib, to physicians and their patients under an early access program approved by the Food and Drug Administration (FDA), according to CEO Mark Goldsmith. "We are now shipping the drug," he stated during a STAT event held in conjunction with the annual meeting of the American Society of Clinical Oncology.
Daraxonrasib is not yet FDA. Patients treated with daraxonrasib lived nearly twice as long compared to those receiving standard chemotherapy – a groundbreaking outcome in the field of pancreatic cancer.
The drug's potential impact on extending patient survival has led many pancreatic cancer patients to eagerly seek early access, underscoring the urgency and importance of this treatment option. Revolution Medicines' decision to launch the drug under an early access program reflects its commitment to providing hope for those battling this aggressive form of cancer.
This development marks a significant step forward in the fight against pancreatic cancer, offering renewed optimism to both patients and medical professionals. As further research continues, daraxonrasib holds promise as a transformative therapy that could potentially change the landscape of pancreatic cancer treatment.
